Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402933 · ClinicalTrials.gov registry record · Phase 3
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
A Phase 3 study of Diabetes Mellitus and Hypoglycemia, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT02402933: Completed Phase 3 study of Diabetes Mellitus and Hypoglycemia, sponsored by Eli Lilly and Company.
NCT02402933 is a Phase 3 study of Diabetes Mellitus and Hypoglycemia that has completed, run by Eli Lilly and Company. The registered enrollment target is 26 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02402933, a Phase 3 study of Diabetes Mellitus and Hypoglycemia, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of Nasal Glucagon (LY900018) in treating episodes of hypoglycemia.
Primary Outcome
Responses to questions completed by the caregiver are used to assess this outcome. An episode of severe hypoglycemia is generally defined as an event associated with severe neuroglycopenia usually resulting in coma or seizure and requiring parenteral therapy (glucagon or intravenous glucose) administered by a third party. In this study moderate hypoglycemia is defined as an episode wherein the child/adolescent with diabetes has symptoms and/or signs of neuroglycopenia and has a blood glucose ≤3.
Conditions Studied
Interventions
- DRUG Nasal Glucagon
Study Locations (3)
Florida
- Private Clinic - Tallahassee
Maryland
- Private Clinic - Baltimore
Massachusetts
- New England Diabetes and Endocrinology Center (NEDEC) - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
What the finished NCT02402933 record still lists
NCT02402933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Nasal Glucagon is the first listed.
NCT02402933 reports a single indexed study location in Florida, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02402933 about?
NCT02402933 is a clinical study titled "Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents". Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of Nasal Glucagon (LY900018) in treating episodes of hypoglycem...
What is the current status of trial NCT02402933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2015-03. Estimated completion is 2015-08.
What conditions does trial NCT02402933 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Hypoglycemia.
What interventions are being tested in trial NCT02402933?
The interventions under investigation include: Nasal Glucagon (DRUG).
Who is sponsoring clinical trial NCT02402933?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02402933 being conducted?
This trial has 3 study locations across Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02402933's enrollment target sits among peer trials
26 184th of 208 higher than 25 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia